Tekla Life Sciences Investors (HQL) 17.01 $HQL
Tekla Funds Announce Results of Joint Annual Shareholders Meeting
BusinessWire - Tue Jun 14, 1:02PM CDT
The Boards of Trustees of Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW) are pleased to announce the results from the Funds' annual shareholder meeting held today.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Life Sciences Investors Paid Distribution
BusinessWire - Fri Jun 10, 9:48AM CDT
On June 10, 2016, Tekla Life Sciences Investors paid a distribution of $0.37 per share. It is currently estimated that this distribution is derived from long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $92,430,063, of which $96,890,977 represents net unrealized appreciation of portfolio securities.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla World Healthcare Fund Paid Distribution
BusinessWire - Tue May 31, 1:45PM CDT
On May 31, 2016, Tekla World Healthcare Fund paid a monthly stock distribution of $0.1167 per share. It is currently estimated that $0.0423 of this distribution is derived from net investment income, $0.0540 from short term capital gains, and $0.0204 from return of capital. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is -$84,598,280, of which $101,111,849 represents net unrealized depreciation of portfolio securities.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Healthcare Opportunities Fund Paid Distribution
BusinessWire - Tue May 31, 1:44PM CDT
On May 31, 2016, Tekla Healthcare Opportunities Fund paid a monthly stock distribution of $0.1125 per share. It is currently estimated that this distribution is derived from short-term capital gains. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is -$58,120,985, of which $68,853,704 represents net unrealized depreciation of portfolio securities.
HQL: 17.01 (-0.27), THQ: 16.14 (-0.14), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Healthcare Investors Paid Distribution
BusinessWire - Thu Mar 31, 11:59AM CDT
On March 31, 2016, Tekla Healthcare Investors paid a distribution of $0.61 per share. It is currently estimated that this distribution is derived from long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $209,865,139, of which $197,524,925 represents net unrealized appreciation of portfolio securities.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Life Sciences Investors (the "Fund"
announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Healthcare Investors Announce Renewal of Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Healthcare Investors (the "Fund" announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Healthcare Opportunities Fund Announces Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Healthcare Opportunities Fund (the "Fund" announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares.
HQL: 17.01 (-0.27), THQ: 16.14 (-0.14), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
H&Q Life Sciences Investors Shares Down 26.2% Since SmarTrend's Sell Call (HQL)
Comtex SmarTrend(R) - Thu Mar 03, 6:46PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 3 months, H&Q Life Sciences Investors has returned 26.23% as of today's recent price of $17.71.
HQL: 17.01 (-0.27)
Tekla Life Sciences Investors Declares Stock Distribution
BusinessWire - Fri Feb 19, 10:22AM CST
On February 19, 2016, Tekla Life Sciences Investors declared a stock distribution of $0.48 per share. The record date for the stock distribution is March 1, 2016 and the payable date is March 31, 2016. The Fund will trade ex-distribution on February 26, 2016.
HQL: 17.01 (-0.27)
H&Q Life Sciences Investors Has Returned 26.5% Since SmarTrend Recommendation (HQL)
Comtex SmarTrend(R) - Wed Feb 03, 6:25PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 2 months, H&Q Life Sciences Investors has returned 26.52% as of today's recent price of $17.64.
HQL: 17.01 (-0.27)
22.1% Return Seen to Date on SmarTrend H&Q Life Sciences Investors Call (HQL)
Comtex SmarTrend(R) - Wed Jan 27, 5:16PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 2 months, H&Q Life Sciences Investors has returned 22.14% as of today's recent price of $18.69.
HQL: 17.01 (-0.27)
H&Q Life Sciences Investors Down 25.6% Since SmarTrend Downtrend Call (HQL)
Comtex SmarTrend(R) - Wed Jan 20, 11:13AM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 1 month, H&Q Life Sciences Investors has returned 25.56% as of today's recent price of $17.87.
HQL: 17.01 (-0.27)
Tekla Funds Announce Results of Joint Annual Shareholders Meeting
BusinessWire - Tue Jun 14, 1:02PM CDT
The Boards of Trustees of Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW) are pleased to announce the results from the Funds' annual shareholder meeting held today.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Life Sciences Investors Paid Distribution
BusinessWire - Fri Jun 10, 9:48AM CDT
On June 10, 2016, Tekla Life Sciences Investors paid a distribution of $0.37 per share. It is currently estimated that this distribution is derived from long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $92,430,063, of which $96,890,977 represents net unrealized appreciation of portfolio securities.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla World Healthcare Fund Paid Distribution
BusinessWire - Tue May 31, 1:45PM CDT
On May 31, 2016, Tekla World Healthcare Fund paid a monthly stock distribution of $0.1167 per share. It is currently estimated that $0.0423 of this distribution is derived from net investment income, $0.0540 from short term capital gains, and $0.0204 from return of capital. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is -$84,598,280, of which $101,111,849 represents net unrealized depreciation of portfolio securities.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Healthcare Opportunities Fund Paid Distribution
BusinessWire - Tue May 31, 1:44PM CDT
On May 31, 2016, Tekla Healthcare Opportunities Fund paid a monthly stock distribution of $0.1125 per share. It is currently estimated that this distribution is derived from short-term capital gains. The composition of this and subsequent distributions may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized depreciation of portfolio securities and net realized gains on sale of securities is -$58,120,985, of which $68,853,704 represents net unrealized depreciation of portfolio securities.
HQL: 17.01 (-0.27), THQ: 16.14 (-0.14), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Healthcare Investors Paid Distribution
BusinessWire - Thu Mar 31, 11:59AM CDT
On March 31, 2016, Tekla Healthcare Investors paid a distribution of $0.61 per share. It is currently estimated that this distribution is derived from long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $209,865,139, of which $197,524,925 represents net unrealized appreciation of portfolio securities.
THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Life Sciences Investors (the "Fund"
announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares. THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Healthcare Investors Announce Renewal of Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Healthcare Investors (the "Fund"
announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares. THQ: 16.14 (-0.14), HQL: 17.01 (-0.27), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
Tekla Healthcare Opportunities Fund Announces Share Repurchase Program
BusinessWire - Thu Mar 24, 3:12PM CDT
Tekla Healthcare Opportunities Fund (the "Fund"
announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 10, 2016. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year period ending July 10, 2017. The Board authorized the share repurchase program as a result of its periodic review of the options available to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the net asset value per share. The share repurchase program is intended to increase the Fund's net asset value per share and could also have the benefit of providing additional liquidity in the trading of shares. HQL: 17.01 (-0.27), THQ: 16.14 (-0.14), THW: 13.91 (-0.16), HQH: 23.63 (-0.39)
H&Q Life Sciences Investors Shares Down 26.2% Since SmarTrend's Sell Call (HQL)
Comtex SmarTrend(R) - Thu Mar 03, 6:46PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 3 months, H&Q Life Sciences Investors has returned 26.23% as of today's recent price of $17.71.
HQL: 17.01 (-0.27)
Tekla Life Sciences Investors Declares Stock Distribution
BusinessWire - Fri Feb 19, 10:22AM CST
On February 19, 2016, Tekla Life Sciences Investors declared a stock distribution of $0.48 per share. The record date for the stock distribution is March 1, 2016 and the payable date is March 31, 2016. The Fund will trade ex-distribution on February 26, 2016.
HQL: 17.01 (-0.27)
H&Q Life Sciences Investors Has Returned 26.5% Since SmarTrend Recommendation (HQL)
Comtex SmarTrend(R) - Wed Feb 03, 6:25PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 2 months, H&Q Life Sciences Investors has returned 26.52% as of today's recent price of $17.64.
HQL: 17.01 (-0.27)
22.1% Return Seen to Date on SmarTrend H&Q Life Sciences Investors Call (HQL)
Comtex SmarTrend(R) - Wed Jan 27, 5:16PM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 2 months, H&Q Life Sciences Investors has returned 22.14% as of today's recent price of $18.69.
HQL: 17.01 (-0.27)
H&Q Life Sciences Investors Down 25.6% Since SmarTrend Downtrend Call (HQL)
Comtex SmarTrend(R) - Wed Jan 20, 11:13AM CST
SmarTrend identified a Downtrend for H&Q Life Sciences Investors (NYSE:HQL) on December 8th, 2015 at $24.01. In approximately 1 month, H&Q Life Sciences Investors has returned 25.56% as of today's recent price of $17.87.
HQL: 17.01 (-0.27)
